StockNews.AI
XGN
StockNews.AI
175 days

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

1. Exagen (XGN) will release Q4 and full-year 2024 financial results on March 11, 2025. Earnings details may influence future evaluations. 2. CEO John Aballi and CFO Jeff Black will host a pre-market conference call. The event is scheduled at 8:30 AM ET. 3. Dial-in and webcast instructions ensure broad investor access. Replay available until April 14, 2025. 4. Article highlights Exagen’s leadership in autoimmune diagnostics with flagship AVISE CTD. The technology aids early diagnosis of complex conditions.

Earnings
+2.03%Current Return
VS
+0.04%S&P 500
$3.4502/25 04:09 PM EDTEvent Start
$3.5202/26 10:57 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Earnings release events historically generate volatility, but pre-announcement news typically yield a neutral impact until results are disclosed. Prior similar events saw transient movement reflecting actual performance.

How important is it?

The scheduled earnings release is a key event for XGN, yet it is a routine announcement. The impact depends on upcoming financial results, making it moderately important.

Why Short Term?

Earnings announcements generally affect short-term price movements until detailed operational impacts are reflected in subsequent guidance and market response.

Related Companies

DGXLH
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com. A replay of the conference call will be available until Monday, April 14, 2025, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13751928. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes. About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X. Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525

Related News